{"id":2558,"date":"2026-08-14T09:00:00","date_gmt":"2026-08-14T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=2558"},"modified":"2026-08-14T18:30:58","modified_gmt":"2026-08-14T22:30:58","slug":"ema-details-trial-misconduct-behind-tavneos-eu-revocation","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=2558","title":{"rendered":"EMA Details Trial Misconduct Behind Tavneos EU Revocation"},"content":{"rendered":"

Company:<\/strong> Amgen · Event Type:<\/strong> Regulatory Action (Negative) · Product\/Asset:<\/strong> Avacopan (Tavneos) · EU Revocation Decision:<\/strong> August 6, 2026 · EMA Reasoning Published:<\/strong> August 14, 2026<\/p>\n

\"EMA<\/p>\n

Summary<\/h4>\n

The European Medicines Agency published its scientific reasoning for revoking the European marketing authorization of Amgen’s avacopan (Tavneos), citing serious breaches of clinical trial conduct in the drug’s pivotal study—including unblinded access to efficacy data and re-adjudication of nine patients’ outcomes that changed a non-significant week-52 result into a statistically significant one. The finding follows a formal European Commission revocation decision on August 6, 2026, and parallels ongoing U.S. FDA scrutiny of the same pivotal trial, whose supporting publication NEJM retracted in June 2026.<\/p>\n

What Happened<\/h4>\n

The European Medicines Agency published a regulatory document detailing the scientific conclusions behind the European Commission’s decision, adopted August 6, 2026, to revoke the marketing authorization for avacopan (Tavneos) across the European Union and European Economic Area, per the agency’s posted document and a related release from CSL Vifor, which holds European marketing rights.<\/p>\n

According to the EMA’s document, study personnel from ChemoCentryx—which developed Tavneos before Amgen’s 2022 acquisition of the company for $3.7 billion—viewed unblinded efficacy findings after the pivotal trial’s database had been locked and identified that superiority at week 52 had not been demonstrated. Following that unblinding, nine patients were re-adjudicated based on knowledge of treatment outcomes, after which the primary analysis was rerun, changing the result from non-significant to statistically significant for week-52 superiority. The EMA stated these changes were not disclosed to regulators, and that the clinical study report filed with the agency stated the unblinding process outlined in the protocol had been followed. The agency concluded it could not isolate the breach’s impact to specific portions of the data package, rendering the study as a whole unreliable, and that results provided at the time of application were incorrect and misleading; it found no feasible condition under which Tavneos would have a positive risk-benefit profile.<\/p>\n

The finding parallels an ongoing separate action by the U.S. FDA, which requested Amgen voluntarily withdraw Tavneos in January 2026 and, in April 2026, alleged the pivotal trial’s data had been manipulated to make the drug appear effective; NEJM retracted the paper reporting the pivotal trial’s results in June 2026 over study-integrity concerns. Amgen has requested an FDA hearing and continues to market Tavneos in the United States, where second-quarter 2026 revenue grew 36% year-over-year to $150 million.<\/p>\n

Nature of the Defect: Data Integrity, Not Marginal Efficacy<\/h4>\n

This is a data-integrity finding, not merely a marginal efficacy question. The EMA’s account describes unblinded personnel altering patient-outcome adjudications after seeing which treatment arm patients were in, then rerunning statistics with those revised adjudications, in a manner not disclosed to regulators and inconsistent with the filed clinical study report’s description of the unblinding process. If accurate as described, this describes conduct that undermines the core evidentiary basis for any efficacy claim from the trial, independent of whatever the raw clinical data might show.<\/p>\n

It is important to separate the underlying clinical question—whether avacopan has meaningful efficacy in ANCA-associated vasculitis, the disease for which Tavneos was originally approved in 2021—from the regulatory finding, which is that the pivotal trial supporting that approval cannot be relied upon due to conduct breaches. The EMA’s inability to isolate the breach’s impact to a subset of the data means the agency is not asserting the drug is definitively inactive, but rather that the trial cannot support a risk-benefit conclusion either way. This is a materially more severe finding than a routine missed endpoint and should not be understated as merely disappointing trial data.<\/p>\n

Reading the Signal<\/h4>\n

Amgen continues to market and defend Tavneos in the United States and has requested a formal FDA hearing with new data and patient testimony, while U.S. revenue for the drug continued to grow (36% year-over-year to $150 million in Q2 2026) even as the EU authorization was withdrawn. This divergence reflects different regulatory postures and procedural stages rather than a substantive disagreement about the underlying facts, since the FDA has separately alleged data manipulation in the same pivotal trial and NEJM has already retracted the associated publication; the more relevant near-term catalyst is the outcome of Amgen’s requested FDA hearing.<\/p>\n

Tavneos represented approximately 1% of Amgen’s 2025 revenue according to prior reporting, meaning the direct revenue impact of the EU withdrawal is limited at the corporate level even though it is significant for the ANCA-vasculitis franchise specifically and for the roughly $3.7 billion ChemoCentryx acquisition that brought Tavneos into Amgen’s portfolio. A finding of improperly disclosed trial conduct, if it withstands Amgen’s ongoing challenges, carries potential litigation, reputational, and regulatory-trust implications beyond the single product, though no such extension was addressed in the sources reviewed and should not be assumed.<\/p>\n

What would upgrade this signal:<\/strong> an FDA hearing outcome that upholds the EMA’s data-integrity findings, which would confirm the issue as global rather than jurisdiction-specific.
\nWhat would downgrade it:<\/strong> if Amgen’s requested FDA hearing surfaces new data or context that meaningfully narrows the scope of the identified conduct breach to a portion of the dataset that doesn’t affect the drug’s core efficacy claim.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • EMA revokes EU marketing authorization for Amgen’s Tavneos (avacopan), citing unblinded re-adjudication of 9 patients that converted a non-significant week-52 result into a statistically significant one.<\/li>\n
  • EMA states the clinical study report’s description of the unblinding process was inconsistent with what actually occurred, and concludes it cannot isolate the breach’s impact to a subset of the data.<\/li>\n
  • Finding corroborates, rather than conflicts with, a parallel unresolved FDA data-manipulation allegation and a June 2026 NEJM retraction of the pivotal trial’s publication.<\/li>\n
  • Amgen continues to market Tavneos in the U.S. (Q2 2026 revenue +36% YoY to $150M) and has requested a formal FDA hearing; Tavneos represents ~1% of Amgen’s total 2025 revenue.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    The EMA’s published reasoning, combined with the prior NEJM retraction and the FDA’s own allegations of data manipulation in the same pivotal trial, constitutes convergent, multi-source corroboration of a serious clinical trial conduct failure, supporting high confidence that the trial itself is unreliable rather than the subject of a one-sided regulatory dispute. Confidence in how this resolves for Amgen in the United States, and in any broader implications for Amgen’s due diligence process on the ChemoCentryx acquisition or other assets, is low, since Amgen is actively contesting the findings, has requested a formal hearing, and the U.S. regulatory and legal process remains open.<\/p>\n

    Company and Product Background<\/h4>\n

    Amgen is a global biotechnology company that acquired ChemoCentryx in 2022 for approximately $3.7 billion, gaining avacopan (Tavneos), an orally administered complement C5a receptor inhibitor approved in the United States and, until this revocation, in the European Union, for adjunctive treatment of ANCA-associated vasculitis—a group of rare autoimmune diseases in which anti-neutrophil cytoplasmic antibodies drive inflammation and damage in small blood vessels, with kidney involvement a major source of morbidity. Avacopan’s proposed mechanism is blockade of complement-mediated neutrophil activation as a steroid-sparing approach to disease control.<\/p>\n

    Signal Assessment<\/h4>\n

    Importance:<\/strong> High — a full marketing-authorization revocation in a major jurisdiction tied to a data-integrity finding, with an active parallel U.S. regulatory dispute.
    \nDirection:<\/strong> Negative.
    \nConfidence:<\/strong> High on the finding that the pivotal trial’s conduct was compromised, given multiple independent, converging sources (EMA document, FDA allegations, NEJM retraction); lower confidence on downstream commercial and legal consequences, which remain contested and unresolved pending Amgen’s FDA hearing.<\/p>\n","protected":false},"excerpt":{"rendered":"

    The European Medicines Agency published its scientific reasoning for revoking the European marketing authorization of Amgen’s avacopan (Tavneos), citing serious breaches of clinical trial conduct in the drug’s pivotal study\u2014including unblinded access to efficacy…<\/p>\n","protected":false},"author":1,"featured_media":2564,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[180,352,351],"class_list":["post-2558","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-therapeutic-indication","tag-amgen","tag-anca-vasculitis","tag-avacopan"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2558","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2558"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2558\/revisions"}],"predecessor-version":[{"id":2568,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2558\/revisions\/2568"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/2564"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2558"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2558"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2558"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}